Research programme: antiviral immunoglobulins - China Biologic Products

Drug Profile

Research programme: antiviral immunoglobulins - China Biologic Products

Alternative Names: Human Cytomegalovirus Immunoglobulin - China Biologic Products; Varicella Hyperimmune globulins

Latest Information Update: 20 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator China Biologic Products
  • Class Immunoglobulins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cytomegalovirus infections
  • Discontinued Vaccinia virus infections

Most Recent Events

  • 25 Feb 2016 China Biologic Products submits application for clinical trial to the CFDA before February 2016 (China Biologic Products, Form 10-K, February 2016)
  • 03 Dec 2012 Preclinical development is ongoing in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top